MRNS - Marinus Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

437.1M

Cash

199.2M

Avg Qtr Burn

-31.68M

Short % of Float

3.06%

Insider Ownership

0.78%

Institutional Own.

83.77%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ganaxolone (ZTALMY) Details Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ganaxolone Details Tuberous sclerosis complex	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ganaxolone Details Epilepsy, Refractory Status Epilepticus	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ganaxolone Details Established Status Epilepticus	Phase 2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Second generation formulation Details Lennox-Gastaut syndrome	Phase 1 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.